USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Innovations in Biomarker Analytics
Innovations in Biomarker Analytics
Tracking the Market Landscape of Companies Striving to Derive Actionable Insights from the Data Deluge through the incorporation of Artificial Intelligence
14-Oct-2019
North America
$4,950.00
Special Price $3,712.50 save 25 %
Description
Biomarker Analytics has always been one of the most in-demand branches of science relevant to the process of drug discovery and development in the Pharmaceutical Industry. Over the years several advances have been made in the area of biomarker analytics with the aim to accelerate the drug development process. The use of AI-based technology can increase the efficiency of biomarker analytics. With the huge data deluges generated through various platforms such as omics, diagnostics etc., machine learning and deep learning techniques are slowly proving to be highly effective in sifting through data and identifying critical biomarkers through pattern recognition. This global research service provides extensive information about the industry trends, market landscape, latest technological advances and AI-based developments in the biomarker analytics industry that hold immense potential in accelerating the process of drug development in the pharmaceutical industry.
Table of Contents
1.1 Research Objectives
1.2 Research Methodology
1.3 Key Predictions: Biomarker Analytics
2.1 Biomarkers and Their Role in Drug Development Process
2.2 Critical Data Generation Processes Contributing to Biomarker Identification
2.3 Biomarkers Have Multiple Uses in Drug Development Process
3.1 Data Processing and Pattern Recognition Key to Biomarker Analytics
3.2 Possible Data Sources for Biomarker Analytics
3.3 Factors Affecting Use of AI in Biomarker Analytics
3.4 Key Aspects and Processes for The Use of AI for Biomarker Analytics
4.1 Factors Impacting The Use of AI for Biomarker Analytics
4.2 AI Will Have Both Short-Term and Long-Term Effect on Biomarker Analytics
5.1 Increasing Global Life Science Investments in AI startups Focused on Drug Development
5.2 Recursion Pharmaceuticals Has Pulled in The Highest Individual Series Funding Round for AI-Based Drug Discovery
5.3 Benevolent AI Is Currently The Highest Funded AI-based Drug Discovery Venture
6.1 Numerate, NuMedii, and ExScientia Were Some of The Early Movers
6.2 Benevolent AI and Insilico Medicine Were The Trailblazers
6.3 Multiple Research Collaborations Were Agreed in 2016/2017
6.4 GNS Healthcare Reported The Highest Number of Industrial Collaborations in 2017
6.5 Year 2018 Marked The Entry of Multiple AI-based Startups Focused on Biomarker Analytics and Drug Discovery
6.6 Industrial Collaborations Continue to Be A Global Phenomenon Rather Than Regional Ones
6.7 Atomwise Reported The Highest Potential Industrial Collaboration Deal in 2019
6.8 Global Trends Position North America and Europe as Leaders in Applying AI for Biomarkers and Drug Development Process
7.1 Company Profile: NuMedii & Recursion Pharmaceuticals
7.2 Company Profile: GNS Healthcare & Insilico Medicine
7.3 Company Profile: Standigm & twoXAR
7.4 Company Profile: ExScientia & BioXcel Therapeutics
7.5 Company Profile: Benevolent AI & Berg Health
8.1 Growth Opportunity 1: Adoption of AI by The Pharmaceutical Industry for Biomarker Analytics
8Industrial Collaborations Can Lead to Increased Access to Proprietary Databases
8Building More Effective Algorithms and Eliminating Data Bias
9.1 Key Contacts
9.1 Key Contacts (continued)
9.1 Key Contacts (continued)
Legal Disclaimer
Popular Topics
| No Index | No |
|---|---|
| Podcast | No |
| Author | Deepak Jayakumar |
| Industries | Healthcare |
| WIP Number | D8DA-01-00-00-00 |
| Is Prebook | No |